We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Modulation of Visually Evoked Potentials by an Antidepressant

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00263133
First Posted: December 7, 2005
Last Update Posted: June 4, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital Freiburg
  Purpose
12 normal healthy controls will be treated with 50 mg sertraline once daily for three weeks. Early amplitudes of visually evoked potentials will be examined at day 0, 10 and 21 and statistically compared. This study aims to examine a putative modulation of synaptic transmission and plasticity by an antidepressant and is part of a series of studies in healthy individuals and depressed patients.

Condition Intervention
Depression Drug: Sertraline

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Modulation of Visually Evoked Potentials by an Antidepressant

Resource links provided by NLM:


Further study details as provided by University Hospital Freiburg:

Primary Outcome Measures:
  • Amplitudes and latencies of early visually evoked potentials.

Estimated Enrollment: 12
Study Start Date: December 2005
Estimated Study Completion Date: January 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy individuals 18-65 years

Exclusion Criteria:

  • history of affective oder other psyhiatric disorder
  • severe medical condition
  • pregnancy or ineffective contraception
  • active illicit drug use
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00263133


Locations
Germany
Dept. of Psychiatry, University of Freiburg
Freiburg, Germany, 79104
Sponsors and Collaborators
University Hospital Freiburg
Investigators
Principal Investigator: Claus Normann, MD Dept. of Psychiatry, University of Freiburg
  More Information

ClinicalTrials.gov Identifier: NCT00263133     History of Changes
Other Study ID Numbers: VEP-1
EudraCT 2005-005417-37
First Submitted: December 6, 2005
First Posted: December 7, 2005
Last Update Posted: June 4, 2007
Last Verified: May 2007

Keywords provided by University Hospital Freiburg:
Depression
SSRI
Sertraline
synaptic plasticity
visually evoked potentials

Additional relevant MeSH terms:
Depression
Behavioral Symptoms
Antidepressive Agents
Sertraline
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs